PTC Therapeutics board member Dawn Svoronos resigns, enters consulting agreement; bylaws updated

PTC THERAPEUTICS, INC.

Dawn Svoronos resigned from the board effective Dec 6, 2022; no disagreement with the company.
Enters consulting agreement at $300/hour, term through March 31, 2023.
Bylaws amended to permit virtual-only shareholder meetings and adjust proxy procedures.
New exclusive forum provisions: Delaware Chancery for derivative claims, federal courts for Securities Act claims.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dawn Svoronos

director

PTCT · PTC THERAPEUTICS, INC.

Effective: 2022-12-06
Filed: December 6, 2022, 6:59 PM ET

On December 5, 2022, Dawn Svoronos, a member of the board of directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”), notified the Company of her resignation from the Board effective December 6, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dawn Svoronos resigned as director at PTC THERAPEUTICS, INC..

Action: resigned
Role: director

Exact text from the filing

On December 5, 2022, Dawn Svoronos, a member of the board of directors (the “Board”) of PTC Therapeutics, Inc. (the “Company”), notified the Company of her resignation from the Board effective December 6, 2022.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PTC THERAPEUTICS, INC.: Amended and restated bylaws to eliminate stockholder list requirement at meetings, permit remote meetings, update proxy rules, and add exclusive forum provisions (effective 2022-12-05).

Change: bylaw amendment
Effective: 2022-12-05

Exact text from the filing

On December 5, 2022, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately.

View on SEC.gov

Browse all governance changes →

PTC THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-124889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.